Dermira, Inc. (DERM) News

Dermira, Inc. (DERM): $3.56

-0.09 (-2.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add DERM to Watchlist
Sign Up

Industry: Biotech


Ranked

of NR

in industry

Filter DERM News Items

DERM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest DERM News From Around the Web

Below are the latest news stories about Journey Medical Corp that investors may wish to consider to help them evaluate DERM as an investment opportunity.

VYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ Deal

Journey Medical Corporation (NASDAQ: DERM) has acquired Molecule Stabilizing Technology (MST) franchise, including Amzeeq (minocycline) topical foam and Zilxi (minocycline) topical foam from VYNE Therapeutics Inc (NASDAQ: VYNE) The transaction includes cash payments of million and potential milestones of up to 0 million. Approved by the FDA nearly 50 years ago, minocycline is a well-established molecule that has been prescribed, in oral formulation, over 30 million times in the past decade. Amze

Yahoo | January 13, 2022

VYNE Therapeutics Divests Topical Minocycline Assets

Transaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline BRIDGEWATER, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has sold its Molecule Stabilizing Technology (MST™) franchise, including AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline)

Yahoo | January 13, 2022

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform Acquisition expands Journey Medical’s portfolio to nine marketed dermatology products East West Bank Credit agreement expanded to $30.0 million SCOTTSDALE, Ariz., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focus

Yahoo | January 13, 2022

How the stocks of 6 Arizona companies fared after going public in 2021

Six Arizona companies went public this year, including ones in the health care, proptech and car wash industries. See how their shares performed since debuting on public markets.

Yahoo | December 27, 2021

Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

Generated record net revenues of $19.6 million for the third quarter of 2021 Completed initial public offering of common stock and raised $31.2 million in net proceeds SCOTTSDALE, Ariz., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent

Yahoo | December 10, 2021

Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference

SCOTTSDALE, Ariz., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that management will present at the Benzinga Global Small Cap Conference, which is being held virtually from December 8 – 9, 2021. Claude Maraoui, President and Chief Executive Officer, and Ernie

Yahoo | December 7, 2021

Journey Medical Corporation Introduces Expanded Board of Directors

SCOTTSDALE, Ariz., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), expanded the company’s board of directors as part of its recent initial public offering to include four new independent directors: Jeffrey Paley, M.D., Justin Smith, Miranda Toledano and Neil Herskowitz. Lindsay Rosenwald, M.D., Executive Chairman, and Claude Maraoui, President and Chief Executive Officer, re

Yahoo | November 29, 2021

Journey Medical completes IPO with shares below initial pricing

After filing to go public in late October, Scottsdale's Journey Medical completed its initial public offering and is now trading on the Nasdaq, but shares have fallen 18 percent from the IPO price.

Yahoo | November 17, 2021

Journey Medical Corporation Announces Closing of Initial Public Offering

SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced the closing of its initial public offering of common stock of 3,520,000 shares at a public offering price of $10.00 per shar

Yahoo | November 16, 2021

Journey Medical Corporation Prices $35.2 Million Initial Public Offering

SCOTTSDALE, Ariz., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced the pricing of its initial public offering of common stock. Journey Medical’s pricing of its underwritten public offering co

Yahoo | November 12, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4943 seconds.